Inspirevax is dedicated to the betterment of all people through the responsible use of advanced medical technology. We focus on developing vaccines and immunotherapeutics that are safe, effective, affordable and accessible. Specifically, we are exploring the Proteosome Intranasal Technology platform for use as an immunotherapeutic and as an adjuvant for mucosal vaccines.

Inspirevax was founded in 2015 in Laval (Montreal), Quebec by three scientists, Joseph Zimmermann, Christine Jacques and Paul Rice, who have worked together on the Proteosome Technology Platform for more than 15 years.

Currently we are working on two clinical development programs based on the Proteosome Intranasal Technology platform. These are an immunotherapy for the treatment of Alzheimer's Disease and an intranasal Covid vaccine that stimulates mucosal immunity. We are looking for commercial partners as we continue to develop and optimize this platform technology.